| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5725616 | Academic Radiology | 2017 | 5 Pages |
Abstract
Various immune-mediated side effects were detected by F-18 FDG PET-CT in the patients subjected to immunomodulating therapy with ipilimumab. It is essential for the interpreting provider to recognize and differentiate abnormal FDG uptake associated with immune-mediated side effects from hypermetabolic malignant lesions when using F-18 FDG PET-CT for monitoring therapeutic effects of ipilimumab on melanoma lesions.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Jason W. MD, Ramapriya MD, PhD, Fangyu MD, PhD,